Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Korean antiplatelet/antithrombotic agent NQ-304 reappears at recent congress

May 10, 2000

Merck describes factor Xa inhibitors and their use in thromboembolic conditions

May 10, 2000

Pamiteplase, a novel t-PA, offers possibility of single bolus injection

May 8, 2000

Selective thrombin inhibitors described in recent patent by Merck researchers

May 4, 2000

In vivo pharmacological profile of antiplatelet agent CS-747

May 3, 2000

New gpIIb/IIIa inhibitor for i.v. administration with sustained pharmacodynamic effects

May 2, 2000

Preliminary clinical data confirm positive effect of oral heparin dosage form

April 26, 2000

Aventis prepares new selective factor VIIa inhibitors

April 24, 2000

Health Canada approves Aggrenox for prevention of recurrent stroke

April 20, 2000

PEG-hirudin superior to unfractionated heparin for short-term reduction of silent ischemia

April 20, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...